MAARS

Microbes in Allergy and Autoimmunity Related to the Skin

 Coordinatore TYOETERVEYSLAITOS 

 Organization address address: Topeliuksenkatu 41 a A
city: HELSINKI
postcode: 250

contact info
Titolo: Prof.
Nome: Harri
Cognome: Alenius
Email: send email
Telefono: 358305000000
Fax: 358305000000

 Nazionalità Coordinatore Finland [FI]
 Sito del progetto http://www.maars.eu
 Totale costo 7˙827˙362 €
 EC contributo 5˙978˙541 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2010-single-stage
 Funding Scheme CP-FP
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-04-01   -   2015-03-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    TYOETERVEYSLAITOS

 Organization address address: Topeliuksenkatu 41 a A
city: HELSINKI
postcode: 250

contact info
Titolo: Prof.
Nome: Harri
Cognome: Alenius
Email: send email
Telefono: 358305000000
Fax: 358305000000

FI (HELSINKI) coordinator 984˙656.50
2    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Mr.
Nome: Thomas
Cognome: Tinglöv
Email: send email
Telefono: 46852483549
Fax: 4686089280

SE (STOCKHOLM) participant 1˙595˙979.20
3    KING'S COLLEGE LONDON

 Organization address address: Strand
city: LONDON
postcode: WC2R 2LS

contact info
Titolo: Mr.
Nome: Paul
Cognome: Labbett
Email: send email
Telefono: +44 207 848 8184
Fax: +44 207 848 8187

UK (LONDON) participant 856˙468.00
4    HEINRICH-HEINE-UNIVERSITAET DUESSELDORF

 Organization address address: UNIVERSITAETSSTRASSE 1
city: DUSSELDORF
postcode: 40225

contact info
Nome: Martina
Cognome: Kuhlmann
Email: send email
Telefono: 492118000000
Fax: 492118000000

DE (DUSSELDORF) participant 654˙380.00
5    INSTITUT CURIE

 Organization address address: 26, rue d'Ulm
city: PARIS
postcode: 75248

contact info
Titolo: Ms.
Nome: Corinne
Cognome: Cumin
Email: send email
Telefono: +33156 24 66 20
Fax: +33 1 56 24 66 27

FR (PARIS) participant 590˙040.00
6    THE HEBREW UNIVERSITY OF JERUSALEM.

 Organization address address: GIVAT RAM CAMPUS
city: JERUSALEM
postcode: 91904

contact info
Titolo: Ms.
Nome: Jane
Cognome: Turner
Email: send email
Telefono: +972 2 6586676
Fax: +972 2 6513205

IL (JERUSALEM) participant 367˙779.60
7    ICOSAGEN AS

 Organization address address: NOORUSE 9
city: TARTU
postcode: 50411

contact info
Titolo: Ms.
Nome: Liina
Cognome: Marquardt
Email: send email
Telefono: 37256221163
Fax: 3727377077

EE (TARTU) participant 324˙118.80
8    CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

 Organization address address: OLSHAUSENSTRASSE 40
city: KIEL
postcode: 24118

contact info
Titolo: Ms.
Nome: Susanne
Cognome: Neufeldt
Email: send email
Telefono: +49 431 880 7246
Fax: +49 431 880 1560

DE (KIEL) participant 319˙156.80
9    HELSINGIN YLIOPISTO

 Organization address address: YLIOPISTONKATU 4
city: HELSINGIN YLIOPISTO
postcode: 14

contact info
Titolo: Ms.
Nome: Tiina
Cognome: Berg
Email: send email
Telefono: +358 9 19125129
Fax: +358 9 19125044

FI (HELSINGIN YLIOPISTO) participant 158˙462.40
10    Fios Genomics Limited

 Organization address address: Buchanan Street 166
city: Glasgow
postcode: G1 2LS

contact info
Titolo: Dr.
Nome: Gary
Cognome: Rubin
Email: send email
Telefono: +44 131 4724800
Fax: +44 131 6624678

UK (Glasgow) participant 127˙500.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

allergy    scientists    unravel    microbiome    molecular    interactions    responses    transcriptomics    basis    cascade    trigger    inflammatory    genetic    bacteria    psoriasis    immune    host    ad    diseases    form    microbes    pathogen    pathways    burden    cell    environment    microbial    allergic    pso    microbe    onset    atopic    maars    reactions    autoimmune    dermatitis    autoimmunity    reaction    samples    throughput    skin    inflammation   

 Obiettivo del progetto (Objective)

'Allergy and autoimmunity cause increasing burden to societies worldwide. We study the effect of microbiome on the skin, the forefront barrier to environment, on autoimmunity and allergy, using atopic dermatitis (AD) and psoriasis (PSO) as paradigmatic examples. We have detailed information about the genetic risk factors, as well as the molecular and cellular players in AD and PSO, but we know very little how microbe-host interaction triggers and regulate inflammatory cascade leading to allergic or autoimmune reaction. We propose that environmental and genetic factors, characteristic to particular disease, initiate a cascade of inflammatory events through the modulation of anti-microbial defence. The dysregulation of innate as well as adaptive immune responses leads to inappropriate responses to physical, microbial or allergen challenge, finally manifesting in the clinical symptoms of AD or PSO. We propose to use high-throughput whole microbiome and transcriptomics analysis with bioinformatics and systems biology to unravel the pathways during the host-pathogen interactions which may trigger an allergic or autoimmune reaction. We will identify key microbes and molecular targets to develop novel intervention strategies to decrease and prevent the burden of allergy and autoimmunity.'

Introduzione (Teaser)

By obtaining mechanistic insights into the early processes underlying chronic inflammation, European scientists wish to understand the onset and progression of allergic or autoimmune diseases. Information generated will form the basis for the development of preventive or treatment measures for atopic dermatitis (AD) and psoriasis (PSO).

Descrizione progetto (Article)

Our immune system has evolved to attack foreign pathogens while at the same time recognising self-antigens. However, inadequate immune responses could lead to the development of allergic reactions or autoimmunity. Accumulating evidence indicates that microbial infections and dysbiosis (microbial imbalance) are critical determinants of the emergence of allergy or autoimmunity.

To unravel inflammatory pathways of host-pathogen interactions that may trigger allergic or autoimmune inflammation, scientists of the EU-funded 'Microbes in allergy and autoimmunity related to the skin' (MAARS) project have chosen to study AD and PSO as paradigm diseases. For this purpose, MAARS researchers are collecting patient skin samples (swab and biopsies) to make sense of the role of the skin microbiome in the pathogenesis of these diseases.

State-of-the-art high-throughput sequencing (HTS) of 16S ribosomal RNA is being used as a means for identifying the different bacteria species present in these samples. Partners are also analysing the microbe-regulated pathways in AD and PSO by DNA microarrays with data from 90 samples currently being annotated.

Work towards the immune aspect of AD and PSO includes the investigation of pathogen-derived triggering mechanisms resulting in the initiation of allergic or autoimmune skin reactions. This entails analysis of the impact of the microbial environment on dendritic cell functions as well as the role of T cell cytokines.

Preliminary experiments in an animal model of AD show that the dermal microbiome is central to the type of elicited T cell responses that determine the onset of allergy. In a similar way, the establishment of psoriasis models will aid in unveiling the importance of bacteria in the development of autoimmunity.

The translational component of the project involves the selection of a series of membrane and secreted proteins as targets for the production of antibodies. Following validation, some of these targets could form the basis for the future design of vaccines.

Taken together, MAARS project activities will link transcriptomics, microbiomics and genetics to provide a multi-parameter analysis of allergy and autoimmunity. Given the epidemic proportions of AD and PSO, and their significant health care costs, the study outcomes will contribute towards the alleviation of these and other allergic or autoimmune diseases.

Altri progetti dello stesso programma (FP7-HEALTH)

MULEVACLIN (2013)

Clinical Studies on a Multivalent Vaccine for Human Visceral Leishmaniasis

Read More  

NIMBL (2010)

"Nuclease Immune Mediated Brain and Lupus-like conditions (NIMBL): natural history, pathophysiology, diagnostic and therapeutic modalities with application to other disorders of autoimmunity"

Read More  

DDPDGENES (2012)

Identification of genes important for human midbrain dopamine neuron development and Parkinson’s disease

Read More